Back to Results

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Primary Objective

To estimate the efficacy, safety, tolerability and reactogenicity of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults. To see if you qualify for the study, please visit this webpage: http://bit.ly/covid19vaccinestudy

Study category: Infectious Diseases

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Scope

National

Locations

Greeley Campus
Medical Center of the Rockies
Poudre Valley Hospital

Principal Investigator
Gary Luckasen

Gary Luckasen

Study ID

Protocol Number: 20-9990

More information available at ClinicalTrials.gov: NCT04516746

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers